The obtained bispecific diabody, after fusion with the low-density lipoprotein receptor-binding domain of the apolipoprotein B for enhancing the transfer across the BBB, was capable of reducing amyloid burden in APP/PS1 transgenic mice [65]. The gene discussed is APP; the disease is amyloidosis.